Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:31 AM
Ignite Modification Date:
2025-12-25 @ 12:31 AM
NCT ID:
NCT06160167
Eligibility Criteria:
Inclusion Criteria:
* Participants ≥18 years of age at index date
* Participants with new diagnosis of MM as defined by:
* ICD-9-CM: 203.0x and/or ICD-10-CM: C90.0x or C90 during the study period
* At least two documented clinical visits for MM on different days and occurring on or after January 1, 2011
* Participants who received at least one systemic MM therapy on or after initial MM diagnosis
* Participants who did not receive clinical study drug at any time during the observation period
* Participants with race information
Exclusion Criteria:
* Exclusion Criteria
* Patients with less than 6 months of medical data during the prior or follow-up period
* Patients in more than one race category (mix race), missing race, unknown race, and "other" race
* Patients diagnosed with the following hematological cancers on or prior to the index date:
* myelodysplastic syndromes (ICD-9: 238.74, 238.75; ICD-10: D46.xx)
* mantle cell lymphoma (ICD-9: 200.4x, ICD-10: C83.1x)
* follicular lymphoma (ICD-9: 202.0x, ICD-10: C82.xx)
* marginal zone lymphoma (ICD-9: 200.3x, ICD-10: C83.4x)
* Patients with evidence of skin hyperpigmentation (ICD-9: 709.00, 709.09; ICD-10: L81.0, L81.1, L81.4, L81.8) on or prior to the index date
* 709.00 Dyschromia, unspecified
* 709.09 Other dyschromia
* L81.0 Post inflammatory hyperpigmentation
* L81.1 Chloasma/melasma
* L81.4 Other melanin hyperpigmentation
* L81.8 Other specified disorders of pigmentation
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06160167
Study Brief:
Protocol Section:
NCT06160167